Anti-AgingFDA-approved

SS-31 (Elamipretide) Therapy: Complete Guide

SS-31, known clinically as elamipretide (brand name Forzinity), is the first FDA-approved mitochondrial-targeted peptide. Approved in September 2025 for Barth syndrome — a rare genetic mitochondrial disease — elamipretide selectively binds to cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain and reducing reactive oxygen species. Off-label interest in SS-31 has surged among longevity clinics for age-related mitochondrial dysfunction, heart failure with preserved ejection fraction, and neurodegenerative conditions.

Typical cost: $500 - $1200/month

What is SS-31 (Elamipretide)?

What Is SS-31 / Elamipretide?

SS-31 is the research designation for a mitochondrial-targeted peptide now approved under the generic name elamipretide and brand name Forzinity. Approved by the FDA in September 2025 for Barth syndrome — a rare X-linked mitochondrial disease — elamipretide became the first mitochondrial-targeted drug ever approved by the FDA. This milestone has opened the door to off-label longevity and cardiology applications that are now a major focus of peptide therapy clinics and anti-aging medicine.

Mitochondrial Dysfunction and Aging

Mitochondria are the cellular power plants that produce ATP via oxidative phosphorylation. With age, mitochondrial efficiency declines, reactive oxygen species (ROS) accumulate, and cardiolipin — a unique phospholipid in the inner mitochondrial membrane — becomes damaged. This decline is central to many age-related conditions: heart failure, neurodegeneration, sarcopenia, and metabolic syndrome. SS-31 selectively concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, preserving mitochondrial structure and function.

Clinical Context

The Barth syndrome approval was based on the TAZPOWER trial demonstrating improvements in muscle strength and functional capacity. Since approval, elamipretide has expanded rapidly into off-label use for age-related mitochondrial dysfunction, heart failure with preserved ejection fraction (HFpEF), primary mitochondrial myopathy, and neurodegenerative disease — although these indications do not yet have FDA approval.

How SS-31 (Elamipretide) Works

Cardiolipin Binding

SS-31 is a small, positively-charged tetrapeptide that selectively accumulates in the inner mitochondrial membrane — the only cellular location where the unusual phospholipid cardiolipin is concentrated. SS-31 binds cardiolipin directly, stabilizing its structure and protecting it from oxidative damage.

Electron Transport Chain Preservation

Cardiolipin is essential for the assembly and stability of respiratory chain supercomplexes — the multi-protein assemblies that perform oxidative phosphorylation. By stabilizing cardiolipin, SS-31 preserves the efficiency of ATP production and reduces the electron leak that generates reactive oxygen species.

Reactive Oxygen Species Reduction

By improving electron transport chain coupling, SS-31 reduces ROS generation at its source rather than scavenging ROS downstream (as conventional antioxidants do). This is a more mechanistically efficient approach to mitigating oxidative stress.

No Membrane Depolarization

SS-31 accumulates in mitochondria via cardiolipin binding rather than membrane potential — meaning it concentrates in mitochondria without requiring or disturbing the membrane potential gradient that conventional mitochondrial-targeted antioxidants (like MitoQ) depend on.

Benefits & Uses

Approved Indication Benefits

Barth syndrome: TAZPOWER demonstrated improvements in functional exercise capacity (six-minute walk distance), muscle strength, and patient-reported outcomes.

Off-Label and Research Applications

Heart failure with preserved ejection fraction (HFpEF): Improvements in cardiac energetics, diastolic function, and exercise tolerance in trial populations.
Age-related mitochondrial dysfunction: Preclinical and early human data suggest improvements in skeletal muscle mitochondrial function.
Primary mitochondrial myopathies: Limited but encouraging data in various rare mitochondrial diseases.
Dry age-related macular degeneration: ReCLAIM-2 trial underway.
Neurodegenerative disease: Preclinical studies in Alzheimer's and Parkinson's models show mitochondrial preservation.
Ischemia-reperfusion injury: Preclinical cardioprotective effects following myocardial infarction.

Why SS-31 Matters for Longevity

Mitochondrial dysfunction is recognized as one of the hallmarks of aging. A drug that directly addresses mitochondrial efficiency — rather than downstream consequences — represents a mechanistically-aligned anti-aging intervention. Expect long-term human longevity data to emerge over the next 3–5 years.

Clinical Evidence & Research

TAZPOWER — Barth Syndrome

Pivotal trial supporting FDA approval. Demonstrated meaningful improvements in functional capacity and muscle strength in Barth syndrome patients, a disease characterized by tafazzin mutations that disrupt cardiolipin remodeling.

HFpEF Trials

Multiple Phase 2 trials in heart failure with preserved ejection fraction have reported improvements in cardiac ATP production (measured by phosphorus-31 MRS), left ventricular function, and exercise capacity. Larger confirmatory trials are ongoing.

ReCLAIM Series — Age-Related Macular Degeneration

Phase 2 data in dry AMD showed improvements in low-luminance visual acuity and reduction in geographic atrophy progression, though results have been variable across trials.

Primary Mitochondrial Myopathy

MMPOWER-3 trial reported mixed results; the heterogeneity of primary mitochondrial diseases makes this population challenging. Continued study ongoing.

Preclinical Evidence

Extensive preclinical literature supports cardioprotection (myocardial infarction, heart failure), neuroprotection (Alzheimer's, Parkinson's), and renoprotection (acute kidney injury, ischemia-reperfusion).

Side Effects & Safety

Common Side Effects

Injection-site reactions — the most common adverse event; mild redness, swelling, or irritation.
Headache — usually mild.
Mild gastrointestinal symptoms — nausea or diarrhea, typically transient.

Serious Adverse Events

In clinical trials to date, serious adverse events attributable to elamipretide have been uncommon. The safety profile is generally favorable compared to other peptide therapies.

Cost as a Barrier

The primary barrier to SS-31 use for most patients is cost. Retail pricing for the approved Barth syndrome indication can reach $500,000 per year, though rare-disease insurance coverage, patient assistance programs, and off-label compounded access at substantially lower prices have expanded real-world availability. Off-label use through compounding pharmacies (where legal) is significantly less expensive but not FDA-regulated.

Unknowns

Long-term safety beyond 2–3 years of continuous use is still being characterized. Effects during pregnancy, breastfeeding, and in pediatric populations beyond the Barth syndrome approval are not well established.

Dosing & Administration

FDA-Approved Dosing (Barth Syndrome)

For Barth syndrome, elamipretide is administered at 40 mg subcutaneously once daily, self-administered or caregiver-administered.

Off-Label Longevity and HFpEF Protocols

Off-label clinic protocols vary widely. Typical ranges reported in practice:

5–10 mg daily (low-intensity longevity protocols)
20–40 mg daily (intensive protocols matching Barth dosing)
Cycle lengths of 8–12 weeks followed by breaks, though continuous daily dosing is also used

Administration

Subcutaneous injection in the abdomen, thigh, or upper arm. Site rotation is standard.

Monitoring

For off-label use, common monitoring includes baseline and periodic cardiac function assessment, markers of mitochondrial function (where available), and symptom-based outcome measures. Formal biomarkers of mitochondrial response are still under development.

Find SS-31 (Elamipretide) Providers Near You

Search our directory for qualified providers offering SS-31 (Elamipretide) therapy. Filter by location, telehealth, and more.

Browse Providers

SS-31 (Elamipretide) FAQ

Yes. SS-31 is the research designation; elamipretide is the generic (INN) name; Forzinity is the FDA-approved brand name. All refer to the same mitochondrial-targeted peptide.

FDA-approved elamipretide for Barth syndrome can cost $500,000+ annually at retail, though insurance and patient assistance reduce out-of-pocket costs for the approved indication. Off-label compounded SS-31 through peptide clinics typically costs $500–$1,200 per month depending on dose and pharmacy.

FDA-approved: Barth syndrome. Off-label applications include heart failure with preserved ejection fraction, age-related mitochondrial dysfunction, primary mitochondrial myopathy, dry macular degeneration, and ischemia-reperfusion injury research.

Compounding pharmacies do offer SS-31 for off-label use in some jurisdictions. Because the FDA-approved product is elamipretide under the Forzinity brand, compounding for off-label use exists in a regulatory gray area. Access varies significantly by state and by pharmacy. Verify that your provider works with a reputable 503A or 503B pharmacy.

Both are mitochondrial peptides but act through different mechanisms. SS-31 stabilizes cardiolipin in the inner mitochondrial membrane, preserving electron transport chain efficiency. MOTS-c is a mitochondrial-derived peptide that acts as an exercise mimetic through systemic metabolic signaling. They address different aspects of mitochondrial biology and are sometimes used together.

Most common side effects are mild injection-site reactions. Headache and transient GI symptoms occur occasionally. Serious adverse events have been uncommon in clinical trials. Long-term safety beyond 2–3 years is still being established.